Overview

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium. This study will randomize patients with SHPT and stage 3 or 4 CKD to treatment with calcitriol or paricalcitol, and monitor patients for the incidence of high blood calcium, and effectiveness of SHPT treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Abbott
Feinberg School of Medicine, Northwestern University
Henry Ford Hospital
NorthShore University HealthSystem

Treatments:

Calcitriol
Ergocalciferols